{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:56:48Z","timestamp":1791111408589,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1007\/s11914-004-0018-y","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T22:49:23Z","timestamp":1180133363000},"page":"101-106","source":"Crossref","is-referenced-by-count":11,"title":["Postmenopausal osteoporosis"],"prefix":"10.1007","volume":"2","author":[{"given":"Peter","family":"Selby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"18_CR1","first-page":"293","volume":"1","author":"F Albright","year":"1947","unstructured":"Albright F: Hormones and human osteogenesis. Recent Prog Horm Res 1947, 1:293\u2013353.","journal-title":"Recent Prog Horm Res"},{"key":"18_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA 2002, 288:321\u2013333. A huge, well conducted, double blind randomized controlled trial of HT. This study examines the beneficial and adverse effects of this treatment and concludes that for most women risk of long term treatment will outweigh the benefits.","journal-title":"JAMA"},{"key":"18_CR3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","volume":"290","author":"JA Cauley","year":"2003","unstructured":"Cauley JA, Robbins J, Chen Z, et al.: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial. JAMA 2003, 290:1729\u20131738.","journal-title":"JAMA"},{"key":"18_CR4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","volume":"362","author":"V Beral","year":"2003","unstructured":"Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419\u2013427.","journal-title":"Lancet"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA 2004, 291:1701\u20131712.","journal-title":"JAMA"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1471-0528.2002.01167.x","volume":"109","author":"T Raudaskoski","year":"2002","unstructured":"Raudaskoski T, Tapanainen J, Tomas E, et al.: Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002, 109:136\u2013144.","journal-title":"BJOG"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637\u2013645.","journal-title":"JAMA"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281:2189\u20132197.","journal-title":"JAMA"},{"key":"18_CR9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83\u201391.","journal-title":"Osteoporos Int"},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, et al.: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120\u2013126.","journal-title":"Bone"},{"key":"18_CR11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, et al.: Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189\u20131199.","journal-title":"N Engl J Med"},{"key":"18_CR12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:437\u20131443.","journal-title":"N Engl J Med"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/jc.2003-022029","volume":"88","author":"C Cooper","year":"2003","unstructured":"Cooper C, Emkey RD, McDonald RH, et al.: Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:4609\u20134615.","journal-title":"J Clin Endocrinol Metab"},{"key":"18_CR14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1359\/jbmr.040116","volume":"19","author":"E McCloskey","year":"2004","unstructured":"McCloskey E, Selby P, Davies M, et al.: Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebocontrolled 3-year study. J Bone Miner Res 2004, 19:728\u2013736.","journal-title":"J Bone Miner Res"},{"key":"18_CR15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","volume":"62","author":"JA Stakkestad","year":"2003","unstructured":"Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al.: Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003, 62:969\u2013975.","journal-title":"Ann Rheum Dis"},{"key":"18_CR16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653\u2013661.","journal-title":"N Engl J Med"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434\u20131441. This is a pivotal clinical trial demonstrating the use of PTH on fractures.","journal-title":"N Engl J Med"},{"key":"18_CR18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","volume":"18","author":"R Marcus","year":"2003","unstructured":"Marcus R, Wang O, Satterwhite J, Mitlak B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18\u201323.","journal-title":"J Bone Miner Res"},{"key":"18_CR19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","volume":"283","author":"SR Cummings","year":"2000","unstructured":"Cummings SR, Palermo L, Browner W, et al.: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000, 283:1318\u20131321. A secondary analysis of results in two trials of osteoporosis therapies that has been widely interpreted as indicating that monitoring of bone mineral density is of little clinical utility.","journal-title":"JAMA"},{"key":"18_CR20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207\u20131215.","journal-title":"N Engl J Med"},{"key":"18_CR21","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216\u20131226.","journal-title":"N Engl J Med"},{"key":"18_CR22","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","volume":"88","author":"AB Hodsman","year":"2003","unstructured":"Hodsman AB, Hanley DA, Ettinger MP, et al.: Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212\u20135220.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"18_CR23","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s00198-002-1343-6","volume":"14","author":"EM Brown","year":"2003","unstructured":"Brown EM: Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporos Int 2003, 14(Suppl 3):S25-S34.","journal-title":"Osteoporos Int"},{"key":"18_CR24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S8756-3282(01)00484-7","volume":"29","author":"J Buehler","year":"2001","unstructured":"Buehler J, Chappuis P, Saffar JL, et al.: Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001, 29:176\u2013179.","journal-title":"Bone"},{"key":"18_CR25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jbmr.5650080512","volume":"8","author":"PJ Marie","year":"1993","unstructured":"Marie PJ, Hott M, Modrowski D, et al.: An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogendeficient rats. J Bone Miner Res 1993, 8:607\u2013615.","journal-title":"J Bone Miner Res"},{"key":"18_CR26","first-page":"2060","volume":"87","author":"PJ Meunier","year":"2002","unstructured":"Meunier PJ, Slosman DO, Delmas PD, et al.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis\u2014a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002, 87:2060\u20132066. A pivotal clinical trial demonstrating the use of strontium ranelate in established postmenopausal vertebral osteoporosis.","journal-title":"J Clin Endocrinol Metab"},{"key":"18_CR27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459\u2013468.","journal-title":"N Engl J Med"},{"key":"18_CR28","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1001\/jama.1941.02820220007002","volume":"116","author":"F Albright","year":"1941","unstructured":"Albright F, Smith PH, Richardson AM: Postmenopausal osteoporosis: its clinical features. JAMA 1941, 116:2465\u20132474.","journal-title":"JAMA"},{"key":"18_CR29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.3388021","volume":"241","author":"EF Erikson","year":"1988","unstructured":"Erikson EF, Colvard DS, Berg NJ, et al.: Evidence of estrogen receptors in normal human osteoblast like cells. Science 1988, 241:84\u201386.","journal-title":"Science"},{"key":"18_CR30","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.130200197","volume":"97","author":"NK Shevde","year":"2000","unstructured":"Shevde NK, Bendixen AC, Dienger KM, Pike JW: Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A 2000, 97:7829\u20137834.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","volume":"111","author":"G Eghbali-Fatourechi","year":"2003","unstructured":"Eghbali-Fatourechi G, Khosla S, Sanyal A, et al.: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221\u20131230.","journal-title":"J Clin Invest"},{"key":"18_CR32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","volume":"16","author":"PJ Bekker","year":"2001","unstructured":"Bekker PJ, Holloway D, Nakanishi A, et al.: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16:348\u2013360.","journal-title":"J Bone Miner Res"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-004-0018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-004-0018-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-004-0018-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T15:12:19Z","timestamp":1707923539000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-004-0018-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s11914-004-0018-y","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}